Stocks Comparison
Airsculpt Technologies vs Hims & Hers Health: revenue, profit, margins and growth compared
Airsculpt Technologies brought in $151.8M of revenue in fiscal 2025, Hims & Hers Health $2.3B in fiscal 2025. Revenue changed by -15.8% at Airsculpt Technologies and +59.0% at Hims & Hers Health on the year before, so Hims & Hers Health grew faster. Airsculpt Technologies kept -7.7% of its revenue as net profit, Hims & Hers Health 5.5%. Free cash flow was $692K at Airsculpt Technologies and $57.4M at Hims & Hers Health.
Side by side, latest fiscal year
| AIRS | HIMS | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $151.8M | $2.3B |
| Revenue growth | -15.8% | +59.0% |
| Net income | -$11.7M | $128.4M |
| Net margin | -7.7% | 5.5% |
| Free cash flow | $692K | $57.4M |
| Free cash flow margin | 0.5% | 2.4% |
| Earnings per share (diluted) | -$0.19 | $0.51 |
| Cash | $8.4M | $228.6M |
| Debt | $56M | n/a |
| Price to earnings | n/a | 57.7 |
| Market value | $141.3M | $6.9B |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #271 of 523 · Health care | #99 of 523 · Health care |
Over the years
Questions about Airsculpt Technologies and Hims & Hers Health
Which is bigger by revenue, Airsculpt Technologies or Hims & Hers Health?
Hims & Hers Health is bigger by revenue: $2.3B in fiscal 2025, against $151.8M for Airsculpt Technologies in fiscal 2025.
Which keeps more of its revenue as profit, Airsculpt Technologies or Hims & Hers Health?
Airsculpt Technologies had a net margin of -7.7% in fiscal 2025; Hims & Hers Health had 5.5% in fiscal 2025.
Which grew revenue faster, Airsculpt Technologies or Hims & Hers Health?
In their latest fiscal years revenue changed by -15.8% at Airsculpt Technologies and +59.0% at Hims & Hers Health.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.